Patent Landscape For Hepatitis Issued By WHO 26/09/2014 by Intellectual Property Watch Leave a Comment Share this:Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Facebook (Opens in new window)Click to email this to a friend (Opens in new window)Click to print (Opens in new window)The World Health Organization has published an analysis of the patent situation for new hepatitis treatments, and a call for possible pharmaceutical products for prequalification. The patent landscape follows a resolution from the World Health Assembly requesting the WHO director general to assist member states in ensuring equitable access to quality, effective, affordable and safe hepatitis C treatments, according to the WHO. The WHO is providing analysis for seven treatments: ABT-450, daclatasvir, dasabuvir, ledipasvir, ombitasvir, simeprevir, and sofosbuvir. Patents are held by AbbVie, Bristol-Myers Squibb Company, Gilead Sciences, and Janssen Pharmaceutical Companies of Johnson & Johnson. Working papers identify the most relevant patents with respect to the medicines, and identify in which countries these patents have been filed and granted. Thomson-Reuters has been mandated by the WHO to carry out that analysis. WHO also announced expanded prequalification to hepatitis, inviting along with a number of other agencies, expressions of interest in product evaluation for prequalification. The prequalification announcement is available here. Image Credits: Flickr: Taki Steve Share this:Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Facebook (Opens in new window)Click to email this to a friend (Opens in new window)Click to print (Opens in new window) Related "Patent Landscape For Hepatitis Issued By WHO" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.